Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TAK-850 in Healthy Pediatric Subjects
NCT02367885Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TAK-850 in influenza (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Events, Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) and 3 more. Started Feb 2015; status: completed.
02
Drugs
TAK-850
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02367885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367885.